Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Geng Liu

Ph.D.

Post-doctoral Research Scientist in Cancer Biology

Recent publications

Separate transcription and splicing gene networks are linked and coordinated by the pRb-E2F pathway.

Carr SM. et al, (2026), Nucleic Acids Res, 54

The HDAC inhibitor zabadinostat is a systemic regulator of adaptive immunity.

Liu G. et al, (2023), Commun Biol, 6

Immune modulation underpins the anti-cancer activity of HDAC inhibitors.

Blaszczak W. et al, (2021), Mol Oncol, 15, 3280 - 3298

Arginine methylation expands the regulatory mechanisms and extends the genomic landscape under E2F control.

Roworth AP. et al, (2019), Sci Adv, 5

The Small Molecules Targeting Ubiquitin-Proteasome System for Cancer Therapy.

Ao N. et al, (2017), Comb Chem High Throughput Screen, 20, 403 - 413

Contact information

Email
geng.liu@oncology.ox.ac.uk

Telephone
01865 617096

Research groups

LA THANGUE GROUP